{"id":"alis","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Generic Available","category":"availability"},{"label":"LOE Approaching","category":"status"},{"label":"Lxo Ireland","category":"company"}],"phase":"marketed","safety":{"commonSideEffects":[{"effect":"Diarrhea","drugRate":"2.3%","severity":"common","organSystem":""},{"effect":"Rash","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Cough","drugRate":"1.1%","severity":"common","organSystem":""},{"effect":"Edema (face, hands, or whole body)","drugRate":"0.4%","severity":"common","organSystem":""},{"effect":"Elevated uric acid","drugRate":"0.4%","severity":"common","organSystem":""},{"effect":"Gout","drugRate":"0.2%","severity":"common","organSystem":""},{"effect":"Renal stones","drugRate":"0.2%","severity":"common","organSystem":""},{"effect":"Abdominal pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Dyspepsia","drugRate":"","severity":"common","organSystem":""},{"effect":"Gastroesophageal reflux","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Acute nephropathy","Acute pancreatitis","Angioedema","Anuria","Azotemia","Chronic idiopathic constipation","Dehydration","Diabetes mellitus","Disease of liver","Gout","Hepatic coma","Hepatic failure","Hypercalcemia","Hypercholesterolemia","Hyperkalemia","Hyperparathyroidism","Hyperuricemia","Hypochloremic alkalosis","Hypokalemia","Hypomagnesemia","Hyponatremia","Hypovolemia","Impaired renal function disorder","Low blood pressure","Neonatal hyperbilirubinemia","Neutropenic disorder","Obstruction of bile duct","Pregnancy, function","Renal artery stenosis","Secondary angle-closure glaucoma","Severe Aortic Valve Stenosis","Sympathectomy","Systemic lupus erythematosus"],"seriousAdverseEvents":[{"effect":"Angioedema with respiratory symptoms","drugRate":"0.06%","severity":"serious"},{"effect":"Periorbital edema","drugRate":"0.06%","severity":"serious"},{"effect":"Seizures (tonic-clonic)","drugRate":"","severity":"serious"}]},"trials":[],"aliases":["Amikacin liposome inhalation suspension","ARIKAYCE®"],"company":"Lxo Ireland","patents":[{"applNo":"N021985","source":"FDA Orange Book","status":"Active","expires":"Feb 19, 2026","useCode":"","territory":"US","drugProduct":true,"patentNumber":"8617595","drugSubstance":false},{"applNo":"N021985","source":"FDA Orange Book","status":"Active","expires":"Aug 19, 2026","useCode":"","territory":"US","drugProduct":false,"patentNumber":"8617595*PED","drugSubstance":false}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ALIS","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:52:44.026101+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T01:52:44.026021+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:52:49.604132+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ALIS","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:52:49.991295+00:00"}},"allNames":["alis"],"offLabel":[],"synonyms":[],"timeline":[{"date":"2000-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from Insmed Incorporated to Lxo Ireland"},{"date":"2017-11-14","type":"positive","source":"FDA Orange Book","milestone":"Tekturna approved — EQ 37.5MG BASE"},{"date":"2019-03-22","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 1 manufacturer approved"}],"approvals":[],"ecosystem":[],"mechanism":{"target":"Multidrug resistance protein 1, Cytochrome P450 3A4, Renin","modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"ALIS is a small molecule that binds to a specific protein target, modulating its activity and leading to downstream effects on cellular function."},"commercial":{},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=alis","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=alis","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-31T10:38:43.681373","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:52:51.940573+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"alis","indications":{"approved":[{"name":"Hypertensive disorder","diseaseId":"hypertensive-disorder","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"currentOwner":"Lxo Ireland","drugCategory":"loe-approaching","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04677569","phase":"PHASE3","title":"Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex","status":"COMPLETED","sponsor":"Insmed Incorporated","startDate":"2021-04-01","conditions":["Mycobacterium Infections, Nontuberculous"],"enrollment":425,"completionDate":"2026-01-15"},{"nctId":"NCT04677543","phase":"PHASE3","title":"Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex","status":"COMPLETED","sponsor":"Insmed Incorporated","startDate":"2020-12-22","conditions":["Mycobacterium Infections, Nontuberculous"],"enrollment":99,"completionDate":"2023-05-09"},{"nctId":"NCT05999942","phase":"PHASE1","title":"A Study to Investigate Lung Deposition of Inhaled Amikacin-loaded Liposomes in Healthy Male Participants","status":"COMPLETED","sponsor":"Insmed Incorporated","startDate":"2004-06-02","conditions":["Healthy Volunteers"],"enrollment":6,"completionDate":"2004-06-29"},{"nctId":"NCT01316276","phase":"PHASE3","title":"Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection","status":"COMPLETED","sponsor":"Insmed Incorporated","startDate":"2012-10-05","conditions":["Cystic Fibrosis"],"enrollment":206,"completionDate":"2015-07-16"},{"nctId":"NCT01315678","phase":"PHASE3","title":"Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections","status":"COMPLETED","sponsor":"Insmed Incorporated","startDate":"2012-02-29","conditions":["Pseudomonas Aeruginosa Infection"],"enrollment":302,"completionDate":"2013-09-18"},{"nctId":"NCT02344004","phase":"PHASE3","title":"Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone","status":"COMPLETED","sponsor":"Insmed Incorporated","startDate":"2015-05-27","conditions":["Mycobacterium Infections, Nontuberculous"],"enrollment":336,"completionDate":"2019-04-03"},{"nctId":"NCT02628600","phase":"PHASE3","title":"Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Participated in Study INS-212","status":"COMPLETED","sponsor":"Insmed Incorporated","startDate":"2016-02-05","conditions":["NTM Lung Infection Due to MAC"],"enrollment":163,"completionDate":"2018-10-17"},{"nctId":"NCT01315236","phase":"PHASE2","title":"Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria","status":"COMPLETED","sponsor":"Insmed Incorporated","startDate":"2012-04-19","conditions":["Mycobacterium Infections, Nontuberculous"],"enrollment":90,"completionDate":"2015-06-18"},{"nctId":"NCT00775138","phase":"PHASE2","title":"Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.","status":"COMPLETED","sponsor":"Insmed Incorporated","startDate":"2008-06-24","conditions":["Bronchiectasis"],"enrollment":64,"completionDate":"2009-05-11"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"_patentsChecked":true,"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Insmed Incorporated","relationship":"Original Developer"},{"period":"present","companyName":"Lxo Ireland","relationship":"Current Owner"}],"publicationCount":281,"therapeuticAreas":["Cardiovascular"],"biosimilarFilings":[],"originalDeveloper":"Insmed Incorporated","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":1,"_genericFilersChecked":true,"genericManufacturerList":["Ph Health"],"status":"active","brandName":"ALIS","companyName":"Lxo Ireland","companyId":"lxo-ireland","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:52:51.940573+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}